States
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Marcos Calderon M D P A
Category: Arthritis SpecialistsUsers Rating:
(915) 886-2120525 South Main Street
Anthony, TX 79821
Marcos Calderon M D P A is a business dealing in the Arthritis Specialists industry. Marcos Calderon M D P A is located in Anthony, TX on 525 South Main Street.
Marcos Calderon M D P A telephone number is
(915) 886-2120.
Telefax: No fax number available
Website: No web address available
Are you the business owner? You can edit this listing.
Permalink: (Easy link to this page) Business owner? Promote this listing for your business by linking here.
Marcos Calderon M D P A
:
Address : 525 South Main Street Anthony, TX 79821
(915) 886-2120
No fax number available
Find more local businesses offering Arthritis Specialists
Get driving directions to Marcos Calderon M D P A
Marcos Calderon M D P A User Reviews and Comments
| ||||||||||
Submit a review for Marcos Calderon M D P A
Helpful Tip for: Arthritis Specialists
'Arthritis Specialists' in Anthony are medical experts and doctors who are trained and qualified to treat any type of arthritis. Post detection, a specialist would ideally put his patient on suitable medication and physical therapy.
Recent Business News for: Arthritis Specialists
Approximately a Quarter of Surveyed Rheumatologists Say Data Are Insufficient ...MarketWatch (press release)... (BUSINESS WIRE) -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that following the May 9, 2012 meeting of the US Food and Drug Administration's (FDA) Arthritis ...and more »



